(Q34662907)

3 August 2017

1 reference

title

Extracorporeal photopheresis in chronic graft-versus-host disease (English)

1 reference

3 August 2017

Foss FM

1

1 reference

3 August 2017

Gorgun G

series ordinal

2

1 reference

3 August 2017

Miller KB

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Bone Marrow Transplantation

3 August 2017

published in

1 reference

3 August 2017

volume

29

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

719-725

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703529

3 August 2017

exact match

0 references

cites work

Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

New and experimental therapies for treating graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Chronic graft-versus-host disease: clinical manifestation and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

How I treat chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

New immunosuppressants in BMT/GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Drug therapy for acute graft-versus-host disease prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Photopheresis: clinical applications and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Treatment of severe cardiac allograft rejection with extracorporeal photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Prevention Of Cyclophosphamide-Induced And Spontaneous Diabetes In Nod Mice By Syngeneic Splenocytes Treated With Cytotoxic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Photopheresis: a Clinically Relevant Immunobiologic Response Modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

Cytokine dysregulation as a mechanism of graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

PUVA therapy for chronic cutaneous graft-vs-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Photopheresis for the treatment of cutaneous T-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Photopheresis for Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Induction of human tumor-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703529

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703529

1 reference

Dimensions Publication ID

3 August 2017

1029453442

0 references

1 reference